New Delhi: With coronavirus cases rising in the country, Serum Institute of India (SII) has written to the Union Health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster for adults.
SII Director Prakash Kumar Singh wrote the letter last week, PTI reported quoting officials.
COVID-19 Working Group, headed by Dr NK Arora, had last month recommended the inclusion of Covovax on CoWIN portal as a booster for adults who have received two doses of either Covishield or Covaxin.
India reported 3,641 fresh COVID-positive cases on Monday.
On January 16, Drugs Controller General of India (DCGI) approved the necessary market authorisation for Covovax as a heterologous booster.
Covovax has already been approved by World Health Organisation (WHO) and US Food and Drug Administration (USFDA).
Covovax is manufactured by SII through technology transfer from US-based vaccine maker Novavax.
